Defining the fetal origin of MLL-AF4 infant leukemia highlights specific fatty acid requirements
Author(s) -
Vasiliki Symeonidou,
Hélène Jakobczyk,
Salem Bashanfer,
Camille Malouf,
Foteini Fotopoulou,
Rishi S. Kotecha,
Richard A. Anderson,
Andrew J. Finch,
Katrin Ottersbach
Publication year - 2021
Publication title -
cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.264
H-Index - 154
eISSN - 2639-1856
pISSN - 2211-1247
DOI - 10.1016/j.celrep.2021.109900
Subject(s) - biology , fetus , disease , haematopoiesis , progenitor cell , leukemia , stem cell , bioinformatics , cancer research , computational biology , immunology , genetics , medicine , pregnancy
Summary Infant MLL-AF4-driven acute lymphoblastic leukemia (ALL) is a devastating disease with dismal prognosis. A lack of understanding of the unique biology of this disease, particularly its prenatal origin, has hindered improvement of survival. We perform multiple RNA sequencing experiments on fetal, neonatal, and adult hematopoietic stem and progenitor cells from human and mouse. This allows definition of a conserved fetal transcriptional signature characterized by a prominent proliferative and oncogenic nature that persists in infant ALL blasts. From this signature, we identify a number of genes in functional validation studies that are critical for survival of MLL-AF4+ ALL cells. Of particular interest are PLK1 because of the readily available inhibitor and ELOVL1, which highlights altered fatty acid metabolism as a feature of infant ALL. We identify which aspects of the disease are residues of its fetal origin and potential disease vulnerabilities.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom